2024-03-28T12:11:24Z
https://niigata-u.repo.nii.ac.jp/oai
oai:niigata-u.repo.nii.ac.jp:00011311
2022-12-15T03:44:42Z
453:456
471:537:538:993
肝炎ウイルス検診の費用対効果分析 : 新潟県の検診データから考える
肝炎ウイルス検診の費用対効果分析 : 新潟県の検診データから考える
Cost - effectiveness Analysis of the Screening for Hepatitis C in Niigata pref.
中村, 潤一郎
本文データは学協会の許諾に基づきCiNiiから複製したものである
cost - effectiveness
screening
hepatitis C
Markov model
Niigata pref.
The aim of this study was to clarify the cost - effectiveness of the Japanese screening program for hepatitis C by analyzing the data of Niigata pref. A Markov model was constructed to demon - strate the life expectancy (LE) and the lifetime cost over 30 years. The screening was conducted dividing into two groups, one was assumed to be the general population and the other was to be the high risk group in which people had hepatic dysfunction or received blood transfusions, operations previously. In our cost - effectiveness analysis, LE and the lifetime cost including the screening cost in each group were compared between the case when people received both the screening and the anti - viral therapy (the screening case) , and the case when people received neither the screening nor the anti - viral therapy ( no screening case) . The incremental cost -effectiveness ratio of the screening case in the general population and that in the high risk group were calculated to be \1,900,166/LE gained and \2,039,653/LE gained, respectively, which were lower than the cost - effectiveness threshold of $50,000 (=\5,750,000). When we re - analyzed the cost - effectiveness by changing the parameters in our Markov model, the superiority in the cost - effectiveness of the screening case was unchanged.
新潟医学会
2008-03
jpn
departmental bulletin paper
http://hdl.handle.net/10191/19604
https://niigata-u.repo.nii.ac.jp/records/11311
AN00182415
00290440
新潟医学会雑誌
新潟医学会雑誌
122
3
128
137
https://niigata-u.repo.nii.ac.jp/record/11311/files/110007146300.pdf
application/pdf
766.4 kB
2019-08-06